Allogene Therapeutics
Moutasem Elsheikh is an experienced professional in quality control with a career spanning over two decades in the biotechnology and pharmaceutical industries. Currently, as the Director of Quality Control at Allogene Therapeutics since December 2018, Moutasem provides technical guidance for method development and quality assurance in the context of phase-appropriate cGMP practices and manages materials for viral vectors and mRNA. Previous roles include Associate Director of QC Infrastructure Support at Allogene Therapeutics, Associate Director of Quality Control Methods at Intarcia Therapeutics, and Principal Specialist at Bayer HealthCare, where Moutasem managed projects and developed key assays for regulatory submissions. Early career experiences include contributions to clinical programs and assay development at Berlex Biosciences and a foundational research position at UCSF. Moutasem holds a Master’s degree in Biomedical Laboratory Sciences from San Francisco State University and a Bachelor’s degree in Clinical Chemistry from the University of Khartoum.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.